Medtronic maintains FY26 outlook as diabetes separation reshapes the story

Transcript intelligence

What changed

Medtronic announced a two-step separation of its diabetes business, including an IPO of up to 20% followed by a split-off. Management also said R&D spending would outpace revenue growth for the first time in four years and highlighted a Hugo robot FDA filing for a urologic indication.

Guidance delta

Management maintained FY26 guidance of approximately 5% organic revenue growth and approximately 4% EPS growth excluding tariffs, with performance expected to be back-loaded.

Key takeaways

• Management described Q4 FY25 as strong, with 5.4% organic revenue growth and high-single-digit EPS leverage.
• The planned diabetes separation is expected to improve gross and operating margins by 50–100 basis points and provide a permanent EPS benefit.
• Pulse-field ablation is a central growth initiative, with management targeting $2 billion in sales and near-term double-digit growth.
• Management plans to accelerate R&D and increase sales and marketing investment in selected growth areas.
• The main counterweights are tariffs, tax-rate pressure, mix-related margin effects, and execution around the diabetes separation.

Management priorities

• Advance pulse-field ablation, structural heart, neuromodulation, diabetes, and surgical robotics products
• Execute the two-step diabetes separation involving an IPO of up to 20% followed by a split-off
• Increase R&D faster than revenue and expand sales and marketing for CAS, Ardian, and tibial stimulation
• Progress Simplera Sync, MiniMed Flex, the 8-Series pump, Hugo indications, and Simplicity hypertension coverage